Cirius

Investment area
Novo Ventures
Region
Eastern USA
Date of investment
March 2017

Cirius is a clinical stage biotechnology company developing MSDC-0602, a PPAR sparing thiazolidinedione (TZD) for non-alcoholic hepatosteatosis (NASH).

Cirius

Investment area
Novo Ventures
Region
Eastern USA
Date of investment
March 2017

Cirius is a clinical stage biotechnology company developing MSDC-0602, a PPAR sparing thiazolidinedione (TZD) for non-alcoholic hepatosteatosis (NASH).

Cirius

Investment area
Novo Ventures
Region
Eastern USA
Date of investment
March 2017

Cirius is a clinical stage biotechnology company developing MSDC-0602, a PPAR sparing thiazolidinedione (TZD) for non-alcoholic hepatosteatosis (NASH).